93 related articles for article (PubMed ID: 7831456)
1. Naltrexone plasma levels, clinical response and effect on weight in autistic children.
Gonzalez NM; Campbell M; Small AM; Shay J; Bluhm LD; Adams PB; Foltz RL
Psychopharmacol Bull; 1994; 30(2):203-8. PubMed ID: 7831456
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone in autistic children: a double-blind and placebo-controlled study.
Campbell M; Anderson LT; Small AM; Locascio JJ; Lynch NS; Choroco MC
Psychopharmacol Bull; 1990; 26(1):130-5. PubMed ID: 2196621
[TBL] [Abstract][Full Text] [Related]
3. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children.
Ernst M; Devi L; Silva RR; Gonzalez NM; Small AM; Malone RP; Campbell M
Psychopharmacol Bull; 1993; 29(2):221-7. PubMed ID: 8290669
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.
Kolmen BK; Feldman HM; Handen BL; Janosky JE
J Am Acad Child Adolesc Psychiatry; 1995 Feb; 34(2):223-31. PubMed ID: 7896655
[TBL] [Abstract][Full Text] [Related]
5. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.
Willemsen-Swinkels SH; Buitelaar JK; van Engeland H
Biol Psychiatry; 1996 Jun; 39(12):1023-31. PubMed ID: 8780837
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone in autistic children: behavioral symptoms and attentional learning.
Campbell M; Anderson LT; Small AM; Adams P; Gonzalez NM; Ernst M
J Am Acad Child Adolesc Psychiatry; 1993 Nov; 32(6):1283-91. PubMed ID: 8282676
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone in young autistic children: replication study and learning measures.
Kolmen BK; Feldman HM; Handen BL; Janosky JE
J Am Acad Child Adolesc Psychiatry; 1997 Nov; 36(11):1570-8. PubMed ID: 9394942
[TBL] [Abstract][Full Text] [Related]
8. Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children.
Herman BH; Hammock MK; Arthur-Smith A; Kuehl K; Appelgate K
Dev Pharmacol Ther; 1989; 12(3):118-27. PubMed ID: 2721334
[TBL] [Abstract][Full Text] [Related]
9. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
[TBL] [Abstract][Full Text] [Related]
10. Pimozide in autistic children.
Ernst M; Magee HJ; Gonzalez NM; Locascio JJ; Rosenberg CR; Campbell M
Psychopharmacol Bull; 1992; 28(2):187-91. PubMed ID: 1513923
[TBL] [Abstract][Full Text] [Related]
11. Scales for the assessment of neuroleptic response in schizophrenic children: specific measures derived from the CPRS.
Spencer EK; Alpert M; Pouget ER
Psychopharmacol Bull; 1994; 30(2):199-202. PubMed ID: 7831455
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone and communication skills in young children with autism.
Feldman HM; Kolmen BK; Gonzaga AM
J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):587-93. PubMed ID: 10230191
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
14. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.
Gagliano A; Germanò E; Pustorino G; Impallomeni C; D'Arrigo C; Calamoneri F; Spina E
J Child Adolesc Psychopharmacol; 2004; 14(1):39-47. PubMed ID: 15142390
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
Wasserman S; Iyengar R; Chaplin WF; Watner D; Waldoks SE; Anagnostou E; Soorya L; Hollander E
Int Clin Psychopharmacol; 2006 Nov; 21(6):363-7. PubMed ID: 17012983
[TBL] [Abstract][Full Text] [Related]
16. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
Leboyer M; Bouvard MP; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M
Encephale; 1993; 19(2):95-102. PubMed ID: 8275903
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
[TBL] [Abstract][Full Text] [Related]
18. The effects of naltrexone in autistic children: report of two cases.
Akkök F
Turk J Pediatr; 1995; 37(1):19-23. PubMed ID: 7732604
[TBL] [Abstract][Full Text] [Related]
19. Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder.
Niederhofer H; Staffen W; Mair A
Hum Psychopharmacol; 2003 Jul; 18(5):389-93. PubMed ID: 12858327
[TBL] [Abstract][Full Text] [Related]
20. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
